Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Recruiting

174 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06904131 2025-04-01

A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors

Phase NA Recruiting

20 enrolled

Other solid neoplasm

Gynecological Solid Tumors

NCT05293912 2025-03-18

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Phase 1 Terminated

2 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Recruiting

72 enrolled

Lymphoid

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT05101109 2024-07-31

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Phase 1 Completed

24 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05119257 2024-05-08

InHeAb01

Available

Tumor-Agnostic

Neoplasms

NCT06404736 2024-05-08

QUEEN-Dream

Phase 2 Not yet recruiting

73 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03030287 2020-09-03

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Phase 1 Completed

44 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02298387 2020-08-11

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Phase 1 Completed

71 enrolled

Other solid neoplasm

Advanced Solid Tumor Malignancies

NCT03035253 2020-08-11

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Phase 1 Terminated

16 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04076137 2019-09-03

Targeted T-cell Therapy in Solid Tumors

Phase EARLY_PHASE1 Unknown

10 enrolled

Other solid neoplasm

Malignant Solid Tumor

NCT00014560 2018-05-03

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Terminated

3 enrolled 3 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00467506 2011-11-11

RIT in MTC

Phase 2 Completed

Head & Neck

Thyroid Neoplasms

NCT00149019 2011-04-08

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

Phase 2 Withdrawn

12 enrolled

Other solid neoplasm

Metastatic Solid Tumors

Clinical Trials

LuCa-MERIT-1

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Immunotherapy in Lymphoma

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

InHeAb01

QUEEN-Dream

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Targeted T-cell Therapy in Solid Tumors

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

RIT in MTC

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.